TY - JOUR
T1 - Salvage Islet Auto Transplantation after Relaparatomy
AU - Balzano, Gianpaolo
AU - Nano, Rita
AU - Maffi, Paola
AU - Mercalli, Alessia
AU - Melzi, Raffaelli
AU - Aleotti, Francesca
AU - Gavazzi, Francesca
AU - Berra, Cesare
AU - De Cobelli, Francesco
AU - Venturini, Massimo
AU - Magistretti, Paola
AU - Scavini, Marina
AU - Capretti, Giovanni
AU - Del Maschio, Alessandro
AU - Secchi, Antonio
AU - Zerbi, Alessandro
AU - Falconi, Massimo
AU - Piemonti, Lorenzo
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Background To assess feasibility, safety, and metabolic outcome of islet auto transplantation (IAT) in patients undergoing completion pancreatectomy because of sepsis or bleeding after pancreatic surgery. Methods From November 2008 to October 2016, approximately 22 patients were candidates to salvage IAT during emergency relaparotomy because of postpancreatectomy sepsis (n = 11) or bleeding (n = 11). Feasibility, efficacy, and safety of salvage IAT were compared with those documented in a cohort of 36 patients who were candidate to simultaneous IAT during nonemergency preemptive completion pancreatectomy through the pancreaticoduodenectomy. Results The percentage of candidates that received the infusion of islets was significantly lower in salvage IAT than simultaneous IAT (59.1% vs 88.9%, P = 0.008), mainly because of a higher rate of inadequate islet preparations. Even if microbial contamination of islet preparation was significantly higher in candidates to salvage IAT than in those to simultaneous IAT (78.9% vs 20%, P < 0.001), there was no evidence of a higher rate of complications related to the procedure. Median follow-up was 5.45 ± 0.52 years. Four (36%) of 11 patients reached insulin independence, 6 patients (56%) had partial graft function, and 1 patient (9%) had primary graft nonfunction. At the last follow-up visit, median fasting C-peptide was 0.43 (0.19-0.93) ng/mL; median insulin requirement was 0.38 (0.04-0.5) U/kg per day, and median HbA1c was 6.6% (5.9%-8.1%). Overall mortality, in-hospital mortality, metabolic outcome, graft survival, and insulin-free survival after salvage IAT were not different from those documented after simultaneous IAT. Conclusions Our data demonstrate the feasibility, efficacy, and safety of salvage IAT after relaparotomy.
AB - Background To assess feasibility, safety, and metabolic outcome of islet auto transplantation (IAT) in patients undergoing completion pancreatectomy because of sepsis or bleeding after pancreatic surgery. Methods From November 2008 to October 2016, approximately 22 patients were candidates to salvage IAT during emergency relaparotomy because of postpancreatectomy sepsis (n = 11) or bleeding (n = 11). Feasibility, efficacy, and safety of salvage IAT were compared with those documented in a cohort of 36 patients who were candidate to simultaneous IAT during nonemergency preemptive completion pancreatectomy through the pancreaticoduodenectomy. Results The percentage of candidates that received the infusion of islets was significantly lower in salvage IAT than simultaneous IAT (59.1% vs 88.9%, P = 0.008), mainly because of a higher rate of inadequate islet preparations. Even if microbial contamination of islet preparation was significantly higher in candidates to salvage IAT than in those to simultaneous IAT (78.9% vs 20%, P < 0.001), there was no evidence of a higher rate of complications related to the procedure. Median follow-up was 5.45 ± 0.52 years. Four (36%) of 11 patients reached insulin independence, 6 patients (56%) had partial graft function, and 1 patient (9%) had primary graft nonfunction. At the last follow-up visit, median fasting C-peptide was 0.43 (0.19-0.93) ng/mL; median insulin requirement was 0.38 (0.04-0.5) U/kg per day, and median HbA1c was 6.6% (5.9%-8.1%). Overall mortality, in-hospital mortality, metabolic outcome, graft survival, and insulin-free survival after salvage IAT were not different from those documented after simultaneous IAT. Conclusions Our data demonstrate the feasibility, efficacy, and safety of salvage IAT after relaparotomy.
UR - http://www.scopus.com/inward/record.url?scp=85016580842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016580842&partnerID=8YFLogxK
U2 - 10.1097/TP.0000000000001750
DO - 10.1097/TP.0000000000001750
M3 - Article
C2 - 28358727
AN - SCOPUS:85016580842
VL - 101
SP - 2492
EP - 2500
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 10
ER -